Indianapolis Business Journal

MARCH 28-APRIL 3, 2016

Eli Lilly and Co. is making a play for a market expected to grow to $80 billion by 2020. But to make a dent with its new drug for arthritis, the pharmaceutical giant must prove it’s better than the proven medicines already prescribed, John Russell reports. Also in this week’s issue, Anthony Schoettle takes stock of Visit Indy’s strategy to sink all of its marketing funds for city tourism into digital content. And in A&E Etc., Lou Harry explores the blockbuster exhibit dedicated to 200 years of Indiana art.

Front PageBack to Top

Eli Lilly headquarters

Lilly angles for arthritis blockbuster

Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.

Read More

Battered Auer mutual fund soldiers on

From the Auer Growth Fund’s debut in late 2007 through the end of 2015, its average annualized return was negative 5 percent, while the overall market rose an average of 6.3 percent annually.

Read More

Top StoriesBack to Top

FocusBack to Top

OpinionBack to Top

In BriefBack to Top

Robin Run completes expansion

Robin Run, managed by Brentwood, Tennessee-based Brookdale Senior Living Solutions, added a three-story building that expands its assisted-living and dementia-care services.

Read More